



Review Special Issue Series: Recent Advances in Live Vaccines against Protozoan Parasites

Guest Editor:

Dr. David Arranz-Solís

Animal Health Department,
Faculty of Veterinary Sciences,
Complutense University of
Madrid, Madrid, Spain

Deadline for manuscript
submissions:

closed (1 November 2023)

Message from the Guest Editor

In this Special Issue we would like to focus on **the development, characterization, field trials and efficacy tests of live vaccines developed for protozoan parasites affecting animals and humans, with a special interest in, but not limited to, those related to apicomplexan parasites and/or with zoonotic potential.** To this end, we invite you to submit an **original research** or **review article** to this Special Issue.

The following topics are intended to serve as guidance, and other related subjects are welcome: Vaccines against intracellular parasites (e.g., apicomplexan parasites); Vaccines against extracellular parasites (e.g., flagellates, ciliates); Vaccines using low-virulence strains of protozoan parasites isolated from field samples; Vaccines using genetically modified organisms of protozoan parasites (knockout, exogenous expression of heterologous proteins/antigens, etc.), with a special interest in CRISPR/Cas9 techniques; Vaccines against diseases caused by protozoan parasites that are transmitted to humans through animal products (meat, milk, eggs, etc.)—One health approach.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com